FDA accepts Sun Pharma’s NDA for deuruxolitinib
India-based pharma company Sun Pharmaceutical Industries has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for deuruxolitinib for the treatment of adults with moderate to severe alopecia areata.
The NDA covers an 8mg dose of the drug to be administered twice daily and is based on two pivotal phase 3 trials, THRIVE-AA1 and THRIVE-AA2. Data from the trials has been previously presented at the 2023 American Academy of Dermatology (AAD) annual meeting in March 2023 and the 31st European Academy of Dermatology and Venereology Congress.
The trials demonstrated a consistent and high-level efficacy of the drug in an 8mg dose, with significant differences in the clinically meaningful SALT score for the treatment arm compared to the placebo group.
Treatment with deuruxolitinib was generally well-tolerated.
Nicole Friedland, president and chief executive officer of the National Alopecia Areata Foundation (NAAF), commented: “People living with alopecia areata are dealing with more than just hair loss. Alopecia areata is a chronic autoimmune disease with psychological and emotional effects, and there is still significant unmet medical need in the community. We are excited that the FDA is evaluating another potential treatment option for this serious medical condition.”
Karuna Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its …
Vivos Therapeutics has announced that it has received 510(k) clearance from the US Food and …
FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System
Inflammatix has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device …